Cargando…

Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine

Vaccination is the most effective and well-tolerated method of conferring long-term protection against hepatitis A and B viruses (HAV; HBV). Long-term studies are required to characterize the duration of protection and need for boosters. Following primary immunization of 150 and 157 healthy adults w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Damme, Pierre, Leroux-Roels, Geert, Suryakiran, P., Folschweiller, Nicolas, Van Der Meeren, Olivier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443376/ https://www.ncbi.nlm.nih.gov/pubmed/28281907 http://dx.doi.org/10.1080/21645515.2016.1274473

Ejemplares similares

Persistence of HBsAg‐specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults
por: Van Damme, Pierre, et al.
Publicado: (2019)

Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults
por: Lazarus, Rajeka, et al.
Publicado: (2016)

Persistence and immune memory to hepatitis B vaccine 20 years after primary vaccination of Thai infants, born to HBsAg and HBeAg positive mothers
por: Poovorawan, Yong, et al.
Publicado: (2012)

Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants
por: Budroni, Sonia, et al.
Publicado: (2021)

Ten‐year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age
por: Schwarz, Tino F., et al.
Publicado: (2017)

Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial
por: Vesikari, Timo, et al.
Publicado: (2021)

Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age
por: Silfverdal, Sven A, et al.
Publicado: (2014)

The role of cell-mediated immunity against influenza and its implications for vaccine evaluation
por: Janssens, Yorick, et al.
Publicado: (2022)

LB13. Trivalent Hepatitis B (HepB) Vaccine Yields Superior Seroprotection Rates in Adults: Results from the Phase 3 Double-Blind, Randomized Study Comparing Immunogenicity and Safety of a 3-Dose Regimen of Sci-B-Vac™ and Engerix B® (PROTECT)
por: Vesikari, Timo, et al.
Publicado: (2019)

H5N1 Influenza Vaccine Formulated with AS03(A) Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses
por: Moris, Philippe, et al.
Publicado: (2010)

Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis
por: Van Der Meeren, Olivier, et al.
Publicado: (2015)

Long-term antibody persistence against hepatitis B in adolescents 14–15-years of age vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy
por: Schwarz, Tino F., et al.
Publicado: (2018)

Hepatitis B Vaccines
por: Pattyn, Jade, et al.
Publicado: (2021)

Lasting immune memory against hepatitis B in 12–13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy
por: Behre, Ulrich, et al.
Publicado: (2016)

Detection of H1 Swine Influenza A Virus Antibodies in Human Serum Samples by Age Group
por: Vandoorn, Elien, et al.
Publicado: (2020)

Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region
por: Poovorawan, Y, et al.
Publicado: (2011)

Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2008)

Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials
por: van der Most, Robbert G., et al.
Publicado: (2017)

Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial
por: Leroux-Roels, Geert, et al.
Publicado: (2018)

A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers
por: Quiambao, Beatriz, et al.
Publicado: (2012)

Avidity of Anti-Circumsporozoite Antibodies following Vaccination with RTS,S/AS01(E) in Young Children
por: Olotu, Ally, et al.
Publicado: (2014)

Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non‐responders: Double‐blinded, randomised, controlled phase 2 trial
por: Koc, Özgür M., et al.
Publicado: (2021)

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials
por: De Coster, Ilse, et al.
Publicado: (2021)

Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2023)

Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: A double-blind randomized trial
por: Leroux-Roels, Geert, et al.
Publicado: (2013)

Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults
por: Leroux-Roels, Isabel, et al.
Publicado: (2020)

Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant
por: Waerlop, Gwenn, et al.
Publicado: (2023)

1087 Immunogenicity and Safety of 3-Dose Primary Vaccination with Combined DTPa-HBV-IPV/Hib Vaccine in Canadian Aboriginal and non-Aboriginal Infants
por: Scheifele, David W., et al.
Publicado: (2014)

Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial
por: Sesay, Sanie, et al.
Publicado: (2017)

Antibody and immune memory persistence post infant hepatitis B vaccination
por: Hudu, Shuaibu A, et al.
Publicado: (2013)

Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette–Guérin-Vaccinated Adults
por: van den Berg, Robert A., et al.
Publicado: (2018)

Hepatitis A vaccination and its immunological and epidemiological long-term effects – a review of the evidence
por: Herzog, Christian, et al.
Publicado: (2020)

Immune persistence 17 to 20 years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination
por: Zhao, Yu-Liang, et al.
Publicado: (2019)

Human Immunity and Susceptibility to Influenza A(H3) Viruses of Avian, Equine, and Swine Origin
por: Vandoorn, Elien, et al.
Publicado: (2023)

Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2022)

Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial
por: Aldrich, Cassandra, et al.
Publicado: (2021)

Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis
por: Schenk, Julie, et al.
Publicado: (2021)

Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents
por: Quiambao, Beatriz P., et al.
Publicado: (2017)

Non-invasive Assessment of Vaccine-Induced HPV Antibodies via First-Void Urine
por: Pattyn, Jade, et al.
Publicado: (2020)

1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons
por: Ison, Michael G, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_620sgto3nbtqlci5vth3dfbj6m